Search QAs

Are manufacturers of insurance products expected to identify the target market where insurance products are targeted to legal persons?

How would the Product Oversight and Governance requirements apply in the context of group insurance contracts?

What action are manufacturers expected to take if products are distributed to customers outside of the target market? Examples of appropriate action?

Are manufacturers of insurance products expected to apply the Product Oversight and Governance requirements with regard to insurance products which are distributed by ancillary insurance intermediaries exempted from the scope of the IDD?

How can the manufacturer demonstrate that they have taken into account the level of information available to customers and the financial literacy of customers?

Can EIOPA provide more guidance on how to assess the granularity of the target market?

For investments in private equity funds there is normally not possible to report Quantity in C0130, S.06.02 List of assets. Can it be wise to report just 1.0 in C0130/Quantity or should the cell be left empty?

Legal environment:
According to the balance sheet instructions of Implementing Regulation 2015/2450 the item "Deposits from reinsurers" reflects "amounts (e.g. cash) received from Reinsurer or deducted by the reinsurer according to reinsurance contract".

When a company sells equity there will be a short term cash receivable during the time the shares been sold but the settlement for cash is not made. In the balance sheet S.02.01 it will be reported in R0420/ Any other assets, not elsewhere shown. In S.06.02 List of assets. Our view is that the...